Fundraising Fox
Mitosense
Plymouth, US · Founded 2019 · Delaware corporation
Find your way into Mitosense
Sign up to see every warm intro you have to Mitosense
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mitosense team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
Founders & leadership
CC
Catherine C. BaucomExecutive
XJ
Xianpeng JiangExecutive
BS
Brent SegalNamed on SEC filing
CR
CARLA R. YORKNamed on SEC filing
AE
ANDREW E. FINNNamed on SEC filing
TW
TIDAL W. MCCOYNamed on SEC filing
Board
RE
Richard E. WaldoBoard director
VD
Van D. Hipp Jr.Board director
Reported raises · per SEC filings
Form D private placements$4.4M disclosed across 3 rounds · 2020–2024
▶$3.7MraisedMay 2025 · 16 investors · Other Health CareRule 506(b)
▶$3.7MraisedMay 2025 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard E. WaldoDirector
- Brent SegalExecutive Officer, Director
- Catherine C. BaucomExecutive Officer, Director
- Van D. Hipp Jr.Executive Officer, Director
- Xianpeng JiangExecutive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $3.7M
- Minimum investment
- $10K
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$435KraisedFeb 2023 · 4 investors · BiotechnologyRule 506(b)
▶$435KraisedFeb 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard E. WaldoDirector
- Catherine BaucomExecutive Officer, Director
- Van D. Hipp, Jr.Executive Officer, Director
- Xianpeng JiangExecutive Officer, Director
- Brent M. SegalExecutive Officer, Director
- Offering amount
- $7.4M
- Amount sold
- $435K
- Minimum investment
- $5K
- Sales commissions
- $120K
- Finders' fees
- $120K
- Proceeds to insiders
- $25K
- Placement agents
- Carolina Securities Inc.
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$340KraisedFeb 2021 · 9 investors · BiotechnologyRule 506(b)
▶$340KraisedFeb 2021 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CARLA R. YORKExecutive Officer
- XIANPENG JIANGExecutive Officer, Director
- BRENT M. SEGALDirector
- ANDREW E. FINNExecutive Officer, Director
- TIDAL W. MCCOYExecutive Officer, Director
- VAN D. HIPP, JR.Executive Officer, Director
- CATHERINE BAUCOMExecutive Officer
- Offering amount
- $5M
- Amount sold
- $340K
- Minimum investment
- $5K
- Sales commissions
- $120K
- Finders' fees
- $120K
- Placement agents
- CAROLINA SECURITIES INC.
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
InfusenseInfuSense develops an electrochemical sensing technology platform that detects analytes at sub-therapeutic levels, delivering sample analysis results within minutes. The portable device is designed to bring laboratory-scale testing capabilities into a handheld form factor.
Mito HealthMito Health offers direct-to-consumer health testing and personalized diagnostics, allowing customers to order from 1000+ lab tests, scans, and health kits at transparent, cost-based pricing without requiring a doctor's referral. Members pay a $9/month subscription for access to member pricing, personalized action plans, longitudinal health tracking, and clinician-reviewed guidance through an AI health coach and concierge service.
SisenseSisense provides embedded analytics software that enables teams to integrate data visualization and insights into business applications. The platform serves product development teams and enterprises seeking to build data-driven features into their software products.
Companies working in the same space as Mitosense.
Frequently asked questions
- What does Mitosense do?
- MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
- How much funding has Mitosense raised?
- Mitosense has disclosed $4.4M raised across 3 rounds.
- Where is Mitosense headquartered?
- Mitosense is headquartered in Plymouth, US.